Inferring protein domains associated with drug side effects based on drug-target interaction network.

Hiroaki Iwata, Sayaka Mizutani, Yasuo Tabei, Masaaki Kotera, Susumu Goto, Yoshihiro Yamanishi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Most phenotypic effects of drugs are involved in the interactions between drugs and their target proteins, however, our knowledge about the molecular mechanism of the drug-target interactions is very limited. One of challenging issues in recent pharmaceutical science is to identify the underlying molecular features which govern drug-target interactions. In this paper, we make a systematic analysis of the correlation between drug side effects and protein domains, which we call "pharmacogenomic features," based on the drug-target interaction network. We detect drug side effects and protein domains that appear jointly in known drug-target interactions, which is made possible by using classifiers with sparse models. It is shown that the inferred pharmacogenomic features can be used for predicting potential drug-target interactions. We also discuss advantages and limitations of the pharmacogenomic features, compared with the chemogenomic features that are the associations between drug chemical substructures and protein domains. The inferred side effect-domain association network is expected to be useful for estimating common drug side effects for different protein families and characteristic drug side effects for specific protein domains.

Original languageEnglish
JournalBMC systems biology
Volume7 Suppl 6
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Drugs
Proteins
Protein
Target
Pharmacogenetics
Interaction
Drug interactions
Pharmaceutical Preparations
Drug products
Protein Domains
Classifiers
Pharmaceuticals
Substructure
Classifier

All Science Journal Classification (ASJC) codes

  • Structural Biology
  • Modelling and Simulation
  • Molecular Biology
  • Computer Science Applications
  • Applied Mathematics

Cite this

Inferring protein domains associated with drug side effects based on drug-target interaction network. / Iwata, Hiroaki; Mizutani, Sayaka; Tabei, Yasuo; Kotera, Masaaki; Goto, Susumu; Yamanishi, Yoshihiro.

In: BMC systems biology, Vol. 7 Suppl 6, 01.01.2013.

Research output: Contribution to journalArticle

Iwata, Hiroaki ; Mizutani, Sayaka ; Tabei, Yasuo ; Kotera, Masaaki ; Goto, Susumu ; Yamanishi, Yoshihiro. / Inferring protein domains associated with drug side effects based on drug-target interaction network. In: BMC systems biology. 2013 ; Vol. 7 Suppl 6.
@article{3bbc90f36d48442f9d0ffad7d442de34,
title = "Inferring protein domains associated with drug side effects based on drug-target interaction network.",
abstract = "Most phenotypic effects of drugs are involved in the interactions between drugs and their target proteins, however, our knowledge about the molecular mechanism of the drug-target interactions is very limited. One of challenging issues in recent pharmaceutical science is to identify the underlying molecular features which govern drug-target interactions. In this paper, we make a systematic analysis of the correlation between drug side effects and protein domains, which we call {"}pharmacogenomic features,{"} based on the drug-target interaction network. We detect drug side effects and protein domains that appear jointly in known drug-target interactions, which is made possible by using classifiers with sparse models. It is shown that the inferred pharmacogenomic features can be used for predicting potential drug-target interactions. We also discuss advantages and limitations of the pharmacogenomic features, compared with the chemogenomic features that are the associations between drug chemical substructures and protein domains. The inferred side effect-domain association network is expected to be useful for estimating common drug side effects for different protein families and characteristic drug side effects for specific protein domains.",
author = "Hiroaki Iwata and Sayaka Mizutani and Yasuo Tabei and Masaaki Kotera and Susumu Goto and Yoshihiro Yamanishi",
year = "2013",
month = "1",
day = "1",
doi = "10.1186/1752-0509-7-S6-S18",
language = "English",
volume = "7 Suppl 6",
journal = "BMC Systems Biology",
issn = "1752-0509",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Inferring protein domains associated with drug side effects based on drug-target interaction network.

AU - Iwata, Hiroaki

AU - Mizutani, Sayaka

AU - Tabei, Yasuo

AU - Kotera, Masaaki

AU - Goto, Susumu

AU - Yamanishi, Yoshihiro

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Most phenotypic effects of drugs are involved in the interactions between drugs and their target proteins, however, our knowledge about the molecular mechanism of the drug-target interactions is very limited. One of challenging issues in recent pharmaceutical science is to identify the underlying molecular features which govern drug-target interactions. In this paper, we make a systematic analysis of the correlation between drug side effects and protein domains, which we call "pharmacogenomic features," based on the drug-target interaction network. We detect drug side effects and protein domains that appear jointly in known drug-target interactions, which is made possible by using classifiers with sparse models. It is shown that the inferred pharmacogenomic features can be used for predicting potential drug-target interactions. We also discuss advantages and limitations of the pharmacogenomic features, compared with the chemogenomic features that are the associations between drug chemical substructures and protein domains. The inferred side effect-domain association network is expected to be useful for estimating common drug side effects for different protein families and characteristic drug side effects for specific protein domains.

AB - Most phenotypic effects of drugs are involved in the interactions between drugs and their target proteins, however, our knowledge about the molecular mechanism of the drug-target interactions is very limited. One of challenging issues in recent pharmaceutical science is to identify the underlying molecular features which govern drug-target interactions. In this paper, we make a systematic analysis of the correlation between drug side effects and protein domains, which we call "pharmacogenomic features," based on the drug-target interaction network. We detect drug side effects and protein domains that appear jointly in known drug-target interactions, which is made possible by using classifiers with sparse models. It is shown that the inferred pharmacogenomic features can be used for predicting potential drug-target interactions. We also discuss advantages and limitations of the pharmacogenomic features, compared with the chemogenomic features that are the associations between drug chemical substructures and protein domains. The inferred side effect-domain association network is expected to be useful for estimating common drug side effects for different protein families and characteristic drug side effects for specific protein domains.

UR - http://www.scopus.com/inward/record.url?scp=84908553078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908553078&partnerID=8YFLogxK

U2 - 10.1186/1752-0509-7-S6-S18

DO - 10.1186/1752-0509-7-S6-S18

M3 - Article

C2 - 24565527

AN - SCOPUS:84908553078

VL - 7 Suppl 6

JO - BMC Systems Biology

JF - BMC Systems Biology

SN - 1752-0509

ER -